The compound you provided, [4-[oxo(thiophen-2-yl)methyl]-1-piperazinyl]-(3-pyridinyl)methanone, is a complex organic molecule with a specific chemical structure. It's challenging to provide detailed information about its importance for research without further context.
Here's why:
* **It's not a well-known or widely studied compound:** The name itself suggests a potentially novel molecule, possibly synthesized for a specific research purpose. Its importance would depend on its specific properties and applications.
* **Importance is context-dependent:** A compound's importance relies on its specific activity and relevance to the research being conducted. For example, it could be:
* **A potential drug candidate:** If it exhibits biological activity against a specific disease target.
* **A synthetic intermediate:** Used in the synthesis of other more complex molecules.
* **A tool for studying chemical reactions:** If it provides insights into specific chemical transformations.
**To understand its importance, we need more information:**
1. **What research area is it associated with?** (e.g., drug discovery, materials science, organic chemistry).
2. **What are its potential properties?** (e.g., biological activity, fluorescence, conductivity).
3. **What specific research questions is it addressing?**
**To find more information, I would recommend:**
* **Searching scientific databases:** PubChem, SciFinder, Google Scholar.
* **Checking the associated research publications:** If you have a specific source or publication where this compound is mentioned.
* **Consulting with experts in the relevant field:** Reach out to researchers or chemists working in the area where this compound is being investigated.
By providing more context, you can get a clearer understanding of the importance of this compound for research.
ID Source | ID |
---|---|
PubMed CID | 717145 |
CHEMBL ID | 1337764 |
CHEBI ID | 114686 |
Synonym |
---|
OPREA1_411239 |
CBMICRO_049881 |
OPREA1_680386 |
1-(3-pyridinylcarbonyl)-4-(2-thienylcarbonyl)piperazine |
smr000070473 |
MLS000099058 , |
BIM-0049608.P001 |
EU-0009469 |
STK129308 |
pyridin-3-yl[4-(thiophen-2-ylcarbonyl)piperazin-1-yl]methanone |
CHEBI:114686 |
pyridin-3-yl-[4-(thiophene-2-carbonyl)piperazin-1-yl]methanone |
AKOS000553738 |
HMS2330N21 |
CHEMBL1337764 |
piperazine, 1-(3-pyridinylcarbonyl)-4-(2-thienylcarbonyl)- |
OBJPERSDPVULEI-UHFFFAOYSA-N |
[4-[oxo(thiophen-2-yl)methyl]-1-piperazinyl]-(3-pyridinyl)methanone |
Q27196090 |
SR-01000475539-1 |
sr-01000475539 |
3-pyridyl[4-(2-thienylcarbonyl)piperazino]methanone |
Class | Description |
---|---|
aromatic carboxylic acid | Any carboxylic acid in which the carboxy group is directly bonded to an aromatic ring. |
pyridinemonocarboxylic acid | A monocarboxylic acid in which the carboxy group is attached to a pyridine (or substituted pyridine) ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 1.4125 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |